Summary
The Trump administration announced it will impose 100% tariffs on patented pharmaceuticals to push for lower drug prices and more domestic manufacturing. Companies that agree to make these drugs in the U.S. or enter into specific pricing agreements can receive lower or no tariffs. This move may lead to more companies investing in U.S. drug production.
Key Facts
- The Trump administration plans to use 100% tariffs on patented drugs to encourage price cuts and U.S. manufacturing.
- Companies that agree to produce drugs in the U.S. may receive a reduced tariff of 20% or be exempted.
- The tariffs apply to branded drugs and their active ingredients, but not to lower-cost generics.
- Tariffs are set to begin in 120 days for large companies and 180 days for smaller ones.
- The announcement may push pharmaceutical companies to invest in U.S. production.
- Some foreign companies in Japan, South Korea, Switzerland, and the EU could be affected if they do not enter pricing deals.
- The administration also adjusted tariffs on aluminum, steel, and copper, keeping them at a 50% rate.
